TEM Stock Recent News

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Officer, will participate in a fireside chat on September 8 from 1:05 to 1:40 p.m. EST. A live audio webcast of the conversation.

When a stock moves a lot, how do you control your risk and keep losses small? Here's what we did with Tempus AI.

TEM accelerates its healthcare edge with Paige, Deep 6 AI, and Ambry Genetics acquisitions, expanding data, tech and clinical reach.

BFLY trades at distressed levels with analyst targets signaling sharp upside, while TEM's premium valuation tempers its appeal.

It's certainly no secret that artificial intelligence (AI) has the potential to change, well, everything for most industries. It's already reshaped several sectors, in fact, and promises to reshape even more in the foreseeable future.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, includ.

AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.

This is a look at five stocks to consider buying before November. No, there isn't a major election cycle, but these high short-interest names have bullish market fundamentals and are expected to report their Q3 results in November.

TEM deepens collaborations in oncology and neuroscience using its Lens and Next platforms to accelerate precision medicine.

Tempus AI (NASDAQ: TEM) has already posted a strong 2x gain since its IPO, rising from $37 to $74. Although it trades at a lofty 14x trailing revenue multiple, the company's solid growth trajectory and expanding market opportunity indicate room for continued upside, as outlined below.